Press releases

Additional data from EVOLVE II pivotal trial demonstrate safety and performance in patients with diabetes at one year

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes

Key data from 42 abstracts to include presentations on the WATCHMAN device and the EMBLEM S-ICD system.

Boston Scientific Corporation (NYSE: BSX) announced its pricing of a public offering of senior notes

Recognition from Shingo Institute is the second in two years for a company facility

CEO Mike Mahoney will outline company's unique opportunities to bring forward meaningful innovation

Customized programs to drive operational and care pathway improvements

"We achieved strong results in the first quarter and continue to build global momentum," said CEO Mike Mahoney

MAJESTIC trial meets performance endpoint with compelling results

Collaboration provides patients and physicians a comprehensive portfolio for Deep Brain Stimulation (DBS) therapy

Results published in the Journal of American College of Cardiology

Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the...

Companies plan to accelerate physician training and expand utilization of less-invasive endoscopy technologies in China

Acquisition will bring minimally invasive devices for Endoscopic Ultrasound (EUS) into company portfolio

Novel stroke risk reduction option for indicated patients with atrial fibrillation

Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest

First-of-its-kind alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation

Combined business to advance patient care with leading solutions across major urology categories

New-generation system is designed to optimize procedural efficiency and productivity

Action against Guidant stemmed from Boston Scientific's acquisition

Agreement provides physicians with a comprehensive solution to prepare and treat diseased femoropopliteal vessels

"2014 was another year of significant achievement for Boston Scientific," said Mike Mahoney, chairman and CEO

Implantable cardioverter defibrillators projected to last nearly 12 years, double the battery capacity of other ICDs

Significant relief achieved using Advanced Illumina™ 3D programming software

EVOLVE II trial represents the first successful U.S. pivotal trial of a bioabsorbable polymer stent

System designed for the hysteroscopic removal of interuterine fibroids and polyps

New CPT Category I code facilitates processing for U.S. hospitals and physicians

Data will focus on long-term back pain relief using the Precision Spectra™ Spinal Cord Stimulator (SCS) System and highlight research on stimulation waveforms

"We achieved excellent third quarter results,” said Mike Mahoney, Boston Scientific chairman and CEO

World's first 32-contact SCS surgical leads designed to provide more focused pain relief for patients with chronic pain

PLATINUM diversity trial evaluating performance in women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease

Innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems

Comprehensive clinical data from randomized trials reviewed

Data from REPRISE III clinical trial designed to support U.S. regulatory approval

First DBS system to offer precise neural targeting and a 25-year battery life

No cases of moderate or severe paravalvular aortic regurgitation at one year

Data will focus on areas of significant unmet patient need, including Coronary Artery Disease and Aortic Valve Disease

Acquisition allows Boston Scientific to offer a more complete portfolio of solutions to treat challenging vascular conditions

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure

Companies reach agreement to develop a new and differentiated FFR guidewire and next generation Boston Scientific Rotablator™ RotaWire™

"We had a strong second quarter, delivering balanced growth across our divisions," said CEO Mike Mahoney

Innovative technology adds to company's leading portfolio of treatment options for Coronary Artery Disease

Easy to use imaging system to support planned intravascular ultrasound and fractional flow reserve products

Advanced bare-metal stent provides additional treatment option for interventional cardiologists and patients

European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely

Innovative technology strengthens company's leading portfolio of solutions for peripheral vascular disease

Data presented at the 18th International Congress of Parkinson's Disease and Movement Disorders demonstrate highly significant improvement in motor function for patients with Parkinson's Disease

Data presented at the International Congress of Parkinson's Disease and Movement Disorders demonstrate superior therapeutic window for the treatment of Parkinson's Disease

Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world

Study evaluated Lotus Valve System in symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement